We are live on ! Find out more
VRAX icon

Virax Biolabs
VRAX

5 hedge funds and large institutions have $1.14M invested in Virax Biolabs in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $990K → $1.14M (+$150K)

0.04% more ownership

Funds ownership: 0.01% → 0.05% (+0.04%)

29% less funds holding

Funds holding: 7 → 5 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
5
Holders Change
-2
Holders Change %
-28.57%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$1.17M
2
TSS
Two Sigma Securities
New York
+$19.2K
3
HF
HRT Financial
New York
+$12K

Top Sellers

Rank Fund Capital Flow
1
KI
Kapitalo Investimentos
Brazil
-$858K
2
VF
Virtu Financial
New York
-$35K
3
Millennium Management
Millennium Management
New York
-$11K
4
Renaissance Technologies
Renaissance Technologies
New York
-$8K
5
UBS Group
UBS Group
Switzerland
-$2.53K

VRAX Hedge Fund Activity: Q1 2023 in Review

5 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q1 2023, worth a combined $1.14M — up 15% from $990K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of VRAX and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.17M. The largest seller was Kapitalo Investimentos, exiting entirely with an estimated $858K sold.

  • 5 institutional investors held Virax Biolabs (VRAX) as of Q1 2023, down from 7 in Q4 2022.
  • Funds reported $1.14M of Virax Biolabs stock for Q1 2023, up 15% quarter-over-quarter.
  • 3 funds opened new Virax Biolabs positions in Q1 2023 and 5 closed out, a net change of -2 holders.
  • The largest Virax Biolabs buyer in Q1 2023 was Armistice Capital, an estimated $1.17M added.
  • The largest Virax Biolabs seller in Q1 2023 was Kapitalo Investimentos, an estimated $858K sold.

Based on aggregated 13F filings for Q1 2023.